2-(2-chloro-3-hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide | 1022155-87-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2-chloro-3-hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo-7-hydropurine-6-carboxamide
• 英文别名: 2-(2-chloro-3-hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo-7H-purine-6-carboxamide
• CAS: 1022155-87-8
• 化学式: C₁₉H₁₄ClN₅O₄
• 分子量: 411.804
• InChiKey: SCIKYJVSHZIVIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  131
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Treatment of cancer with TOR kinase inhibitors
  申请人：Signal Pharmaceuticals, LLC

  公开号：US11166950B2

  公开（公告）日：2021-11-09

  Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

  本文提供了治疗或预防患者实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的方法，包括向患有实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的患者施用有效量的TOR激酶抑制剂。
• HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS
  申请人：Signal Pharmaceuticals LLC

  公开号：EP2078018B1

  公开（公告）日：2012-03-14
• TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
  申请人：Signal Pharmaceuticals, LLC

  公开号：EP2768500B1

  公开（公告）日：2019-08-21
• IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS
  申请人：Chopra Rajesh

  公开号：US20110257167A1

  公开（公告）日：2011-10-20

  Provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by a LKB1 and/or AMPK gene or protein loss or mutation.
• US9493466B2
  申请人：——

  公开号：US9493466B2

  公开（公告）日：2016-11-15